Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

EMMANUEL JEAN-MARIE MIGNOT

Allopathic & Osteopathic Physicians Psychiatry & Neurology Sleep Medicine

NPI
1023151800
CMS profile
961917
Location
STANFORD, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$40,598.94

22 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $26,672.50 7
Travel and Lodging $13,012.36 2
Food and Beverage $914.08 13

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Takeda Pharmaceuticals U.S.A., Inc. $36,694.74 12
Daiichi Sankyo Inc. $1,865.35 4
HARMONY BIOSCIENCES LLC $1,563.00 1
JAZZ PHARMACEUTICALS INC. $325.85 3
IDORSIA PHARMACEUTICALS US INC $150.00 2

Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

EMMANUEL JEAN-MARIE MIGNOT

NPI 1023151800 · CMS profile ID 961917

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Sleep Medicine

STANFORD, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1023151800?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
EMMANUEL JEAN-MARIE MIGNOT, NPI 1023151800, CMS profile ID 961917. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1023151800?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). EMMANUEL JEAN-MARIE MIGNOT, NPI 1023151800, CMS profile ID 961917. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1023151800?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
EMMANUEL JEAN-MARIE MIGNOT, NPI 1023151800, CMS profile ID 961917, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1023151800?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

22 matching records · $40,598.94 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 22 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–22 of 22.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Takeda Pharmaceuticals U.S.A., Inc. $4,800.0010/09/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137635792 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,700.0010/09/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137635794 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,700.0010/09/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137635796 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,105.8909/24/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137635782 CMS
Takeda Pharmaceuticals U.S.A., Inc. $55.4309/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137635784 CMS
Takeda Pharmaceuticals U.S.A., Inc. $10,422.0009/24/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137635786 CMS
Takeda Pharmaceuticals U.S.A., Inc. $11,906.4709/24/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137635788 CMS
Takeda Pharmaceuticals U.S.A., Inc. $65.2109/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137635790 CMS
Takeda Pharmaceuticals U.S.A., Inc. $56.0809/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137635780 CMS
Takeda Pharmaceuticals U.S.A., Inc. $98.0109/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137635778 CMS
Daiichi Sankyo Inc. $1,787.5007/24/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089457020 CMS
JAZZ PHARMACEUTICALS INC. $99.6906/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150195586 CMS
IDORSIA PHARMACEUTICALS US INC $87.5006/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146756181 CMS
JAZZ PHARMACEUTICALS INC. $182.8306/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150195588 CMS
Takeda Pharmaceuticals U.S.A., Inc. $85.6506/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137635776 CMS
Daiichi Sankyo Inc. $8.0505/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089457022 CMS
Daiichi Sankyo Inc. $24.1605/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089457024 CMS
Daiichi Sankyo Inc. $45.6405/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089457026 CMS
IDORSIA PHARMACEUTICALS US INC $62.5005/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146756183 CMS
JAZZ PHARMACEUTICALS INC. $43.3305/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150195584 CMS
HARMONY BIOSCIENCES LLC $1,563.0004/04/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126058267 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,700.0001/03/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137635774 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,292.12 9
PY2020 $14,160.00 5
PY2021 $23,131.44 17
PY2022 $2,844.54 7
PY2023 $4,565.65 9
PY2024 $40,598.94 22
PY2025 $47,971.34 26

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $992.00 1
PY2025 Principal investigator $2,401,878.07 533
PY2024 Principal investigator $1,022,037.24 254
PY2023 Principal investigator $275,388.22 59
PY2022 Principal investigator $175,960.37 12
PY2021 Principal investigator $361,355.25 19
PY2020 Recipient $3,276.62 36
PY2020 Principal investigator $214,065.50 29
PY2019 Recipient $921.37 2
PY2019 Principal investigator $67,788.78 53

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

12 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $17.63 12/31/2022 Non-covered Recipient Entity
STANFORD UNIVERSITY
Clinical Trial to Characterize Symptoms of Excessive Daytime Sleepiness Following Treatment Withdrawal in Participants with Narcolepsy Type 1 No dispute reported 06/30/2026 940398829
Principal investigator 1 Vanda Pharmaceuticals Inc. $4,140.00 09/09/2022 Non-covered Recipient Entity
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
EVALUATING THE EFFECTS OF TASIMELTEON VS. PLACEBO IN DELAYED SLEEP-WAKE PHASE DISORDER (DSWPD) No dispute reported 06/30/2026 951892939
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $4,268.16 07/06/2022 Non-covered Recipient Entity
LUCILE PACKARD CHILDREN'S HOSPITAL STANFORD UNIVERSITY
A PHASE 4 MULTICENTER OPEN-LABEL SINGLE-ARM STUDY OF SAFETY TOLERABILITY EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 950368517
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $15,129.22 06/10/2022 Non-covered Recipient Entity
LUCILE PACKARD CHILDREN'S HOSPITAL STANFORD UNIVERSITY
A PHASE 4 MULTICENTER OPEN-LABEL SINGLE-ARM STUDY OF SAFETY TOLERABILITY EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 950368515
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,501.30 05/13/2022 Non-covered Recipient Entity
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A DOSE-BLIND EXTENSION STUDY WITH DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND EXPLORE THE PHARMACOKINETICS AND PHARMACODYNAMICS OF TAK-994 IN ADULTS WITH NARCOLEPSY WITH CATAPLEXY (NARCOLEPSY TYPE 1) No dispute reported 06/30/2026 937168137
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $11,080.00 05/09/2022 Non-covered Recipient Entity
STANFORD SLEEP MEDICINE CENTER
A PHASE 4 MULTICENTER OPEN-LABEL SINGLE-ARM STUDY OF SAFETY TOLERABILITY EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 950368521
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $44,320.00 04/28/2022 Non-covered Recipient Entity
STANFORD SLEEP MEDICINE CENTER
A PHASE 4 MULTICENTER OPEN-LABEL SINGLE-ARM STUDY OF SAFETY TOLERABILITY EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 950368519
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $15,525.80 04/25/2022 Non-covered Recipient Entity
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE RISING ORAL DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-994 IN PATIENTS WITH NARCOLEPSY WITH OR WITHOUT CATAPLEXY (NARCOLEPSY TYPE 1 OR NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 937167319
Principal investigator 1 Vanda Pharmaceuticals Inc. $8,899.00 03/23/2022 Non-covered Recipient Entity
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
EVALUATING THE EFFECTS OF TASIMELTEON VS. PLACEBO IN DELAYED SLEEP-WAKE PHASE DISORDER (DSWPD) No dispute reported 06/30/2026 951890727
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $50,000.00 03/03/2022 Non-covered Recipient Entity
STANFORD UNIVERSITY
IMPROVING ON THE DETECTION OF NARCOLEPSY THROUGH NOCTURNAL PSG ANALYSIS AND ESTABLISHING A SENSITIVE BIOMARKER FOR OREXIN PHARMACOLOGICAL RESPONSES No dispute reported 06/30/2026 937164371
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,160.00 03/02/2022 Non-covered Recipient Entity
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A DOSE-BLIND EXTENSION STUDY WITH DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND EXPLORE THE PHARMACOKINETICS AND PHARMACODYNAMICS OF TAK-994 IN ADULTS WITH NARCOLEPSY WITH CATAPLEXY (NARCOLEPSY TYPE 1) No dispute reported 06/30/2026 937164157
Principal investigator 1 Vanda Pharmaceuticals Inc. $919.26 01/05/2022 Non-covered Recipient Entity
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
EVALUATING THE EFFECTS OF TASIMELTEON VS. PLACEBO IN DELAYED SLEEP-WAKE PHASE DISORDER (DSWPD) No dispute reported 06/30/2026 951889207